To determine if enhancement of infection by the second dose supports increased survival through direct antitumor activity or through modulation of the CD8+ T cell response, we used an antibody-based depletion strategy to reduced CD8+ cell counts in the lymph node, spleen, and tumor by at least 98% (Supplementary Fig. 5a–c). The gene discussed is CD8A; the disease is infection.